title: [MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
abstract: For salvage chemotherapy, 30 cases of relapsed or refractory non-Hodgkin's lymphoma (NHL) were treated with MMIP regimen (mitoxantrone 15 mg/m2, methotrexate 400 mg/m2, and ifosfamide 2 g/m2 intravenously in day 1, respectively, and prednisolone 20 mg/m2 orally from day 1 to 5). The overall complete response rate (CR rate) was 20% and the median survival duration was 153 days. In patients with favorable performance status (PS), the CR rate and survival duration were 30% and 407 days, respectively. These results were almost equivalent to previously proposed salvage regimens. The overall disease free survival rate of CR cases at 4 years was 62%, which was excellent as compared with the other salvage regimens. Five of 8 (62.5%) patients previously treated with etoposide-non-containing regimens achieved CR, and the CR rate was significantly superior to that of patients previously treated with etoposide-containing ones. These results indicate that MMIP is a useful salvage regimen for relapsed or refractory NHL, while it seems to be difficult to salvage patients previously treated with etoposide-containing regimens.
authors.affiliation: 3rd Department of Internal Medicine, School of Medicine, Kanazawa University.
authors.forename: M
authors.initials: M
authors.lastname: Takeshima
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: N
authors.initials: N
authors.lastname: Hattori
authors.forename: H
authors.initials: H
authors.lastname: Kaya
authors.forename: S
authors.initials: S
authors.lastname: Otake
authors.forename: Y
authors.initials: Y
authors.lastname: Okabe
authors.forename: H
authors.initials: H
authors.lastname: Okumura
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Matano
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D002955:Leucovorin / Q000008:administration & dosage*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*; D011239:Prednisolone / Q000008:administration & dosage*; D012008:Recurrence
chemical_list: D011239:Prednisolone; D008942:Mitoxantrone; D002955:Leucovorin; D007069:Ifosfamide; D008727:Methotrexate